Application of the ASCO Value Framework to Evaluate the Clinical and Economic Value of Enzalutamide and Apalutamide in the Early Stages of Prostate Cancer in Colombia

Overview

Journal Ecancermedicalscience

Specialty Oncology

Date 2024 Feb 28

PMID 38414970

Authors

Martin Romero

Andrea Diaz

Karen Sanchez

Sandra Amaya

Fabian Godoy

David Rodriguez

Affiliations

Soon will be listed here.

Abstract

Introduction: Prostate cancer has increased in recent years, increasing the costs associated with its treatment. Second-generation oral antiandrogens have emerged as an attractive therapeutic option.

Objective: To compare the health value provided by enzalutamide and apalutamide, by evaluating two stages of prostate cancer: non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC).

Methods: To establish, through the American Society of Clinical Oncology (ASCO) value framework, a contrast between two technologies in two stages of prostate cancer. The monthly cost of the two technologies was calculated according to the current price regulation norm in Colombia.

Results: Enzalutamide showed a higher net health benefit score compared to apalutamide for both nmCRPC (48.33 versus 33.46) and mHSPC (52.0 versus 40.75). The cost per net health benefit point for the nmCRPC stage was $214,723 Colombian Pesos (COP) ($54.84 USD) with enzalutamide compared to $291,925 COP ($74.56 USD) with apalutamide, and for the mHSPC stage was $199,692 COP ($51.00 USD) with enzalutamide and $239,701 COP ($61.22 USD) with apalutamide.

Conclusion: After comparing enzalutamide versus apalutamide in the nmCRPC and mHSPC stages through the ASCO value framework, enzalutamide showed a more prominent net clinical benefit and a lower investment per point awarded.

References

Saad F, Cella D, Basch E, Hadaschik B, Mainwaring P, Oudard S . Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018; 19(10):1404-1416. DOI: 10.1016/S1470-2045(18)30456-X. View

Schnipper L, Davidson N, Wollins D, Blayney D, Dicker A, Ganz P . Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol. 2016; 34(24):2925-34. DOI: 10.1200/JCO.2016.68.2518. View

Schnipper L, Davidson N, Wollins D, Tyne C, Blayney D, Blum D . American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015; 33(23):2563-77. PMC: 5015427. DOI: 10.1200/JCO.2015.61.6706. View

Smith M, Saad F, Chowdhury S, Oudard S, Hadaschik B, Graff J . Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2020; 79(1):150-158. DOI: 10.1016/j.eururo.2020.08.011. View

Stenzl A, Dunshee C, De Giorgi U, Alekseev B, Iguchi T, Szmulewitz R . Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Eur Urol. 2020; 78(4):603-614. DOI: 10.1016/j.eururo.2020.03.019. View

Zhang M, Bao Y, Lang Y, Fu S, Kimber M, Levine M . What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks. Value Health. 2022; 25(2):302-317. DOI: 10.1016/j.jval.2021.07.005. View

Armstrong A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A . ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019; 37(32):2974-2986. PMC: 6839905. DOI: 10.1200/JCO.19.00799. View

Sathianathen N, Koschel S, Thangasamy I, Teh J, Alghazo O, Butcher G . Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. 2019; 77(3):365-372. DOI: 10.1016/j.eururo.2019.09.004. View

Porter M, Lee T . Why strategy matters now. N Engl J Med. 2015; 372(18):1681-4. DOI: 10.1056/NEJMp1502419. View

10.

Smith M, Saad F, Chowdhury S, Oudard S, Hadaschik B, Graff J . Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378(15):1408-1418. DOI: 10.1056/NEJMoa1715546. View

11.

Tombal B, Saad F, Penson D, Hussain M, Sternberg C, Morlock R . Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2019; 20(4):556-569. DOI: 10.1016/S1470-2045(18)30898-2. View

12.

Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes A, Chung B . Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2019; 20(11):1518-1530. DOI: 10.1016/S1470-2045(19)30620-5. View

13.

Porter M . What is value in health care?. N Engl J Med. 2010; 363(26):2477-81. DOI: 10.1056/NEJMp1011024. View

14.

Cherny N, de Vries E, Dafni U, Garrett-Mayer E, McKernin S, Piccart M . Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. J Clin Oncol. 2019; 37(4):336-349. DOI: 10.1200/JCO.18.00729. View

15.

Chen J, Ni Y, Sun G, Liao B, Zhang X, Zhao J . Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis. Front Oncol. 2020; 10:519388. PMC: 7531177. DOI: 10.3389/fonc.2020.519388. View

16.

Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes A, Chung B . Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study. J Urol. 2021; 206(4):914-923. DOI: 10.1097/JU.0000000000001841. View

17.

Davis I, Martin A, Stockler M, Begbie S, Chi K, Chowdhury S . Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019; 381(2):121-131. DOI: 10.1056/NEJMoa1903835. View

18.

Ng K, Smith S, Shamash J . Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting. Oncol Ther. 2020; 8(2):209-230. PMC: 7683690. DOI: 10.1007/s40487-020-00119-z. View

19.

Chi K, Chowdhury S, Bjartell A, Chung B, Pereira de Santana Gomes A, Given R . Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol. 2021; 39(20):2294-2303. DOI: 10.1200/JCO.20.03488. View

20.

Mori K, Mostafaei H, Pradere B, Sari Motlagh R, Quhal F, Laukhtina E . Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol. 2020; 25(11):1892-1900. PMC: 7572325. DOI: 10.1007/s10147-020-01777-9. View